Amgen Inc. or Ascendis Pharma A/S: Who Manages SG&A Costs Better?

A Tale of Two Biotechs: Amgen Inc. vs. Ascendis Pharma A/S

In the competitive world of biotechnology, managing operational costs is crucial for sustaining growth and innovation. Amgen Inc., a stalwart in the industry, and Ascendis Pharma A/S, a rising star, offer a fascinating study in contrasts when it comes to handling Selling, General, and Administrative (SG&A) expenses. Over the past decade, Amgen's SG&A expenses have shown a steady increase, peaking at approximately $6.2 billion in 2023, reflecting a 31% rise since 2014. In contrast, Ascendis Pharma's SG&A costs, while significantly lower, have surged by over 4,100% from 2014 to 2023, reaching around $264 million. This dramatic increase highlights Ascendis Pharma's rapid expansion and investment in growth. As these two companies navigate the complexities of the biotech landscape, their differing approaches to SG&A management offer valuable insights into their strategic priorities and market positioning.